Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - BTIG initiated coverage on Jade Biosciences (NASDAQ:JBIO), currently trading at $9.08 with a market cap of $296 million, with a Buy rating and a $28.00 price target, citing the potential of its APRIL inhibitors in treating IgA nephropathy (IgAN). InvestingPro data shows the stock has delivered a significant 9% return over the past week.
The research firm believes JADE101 has the opportunity to improve upon previous monoclonal antibodies in its class due to unique pharmacokinetic and pharmacodynamic advantages. BTIG estimates the IgAN market opportunity exceeds $10 billion in the U.S. alone, with limited treatment options that directly address the disease’s cause. According to InvestingPro, the company maintains strong financial flexibility with a current ratio of 5.81, indicating ample liquidity to fund its development programs.
BTIG notes that Jade’s leadership team includes a CEO and CSO previously part of Chinook Therapeutics, which Novartis acquired in August 2023 for $3.2 billion upfront. This experience in the nephrology space adds credibility to Jade’s development program.
The firm expects JADE101’s differentiated features—including higher binding affinity, slower off-rate, novel epitope, and YTE-modification—to potentially deliver class-leading clinical results. A Phase 1 trial in healthy volunteers is ongoing with interim data expected in the first half of 2026. Investors should note that the company’s next earnings report is scheduled for November 13, 2025, with analyst price targets ranging from $14 to $19, suggesting potential upside from current levels.
BTIG also highlighted Jade’s recently announced antiBAFF-R monoclonal antibody JADE201, which it believes has thoughtful improvements versus ianalumab and is well-positioned across B-cell mediated autoimmune diseases, with a first-in-human trial expected to begin in the first half of 2026.
In other recent news, Jade Biosciences has introduced JADE201, a new investigational monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R) for autoimmune diseases. This antibody is designed to offer deeper B cell depletion with less frequent dosing. In addition to unveiling JADE201, Jade Biosciences has secured approximately $135 million through a private investment in public equity (PIPE) financing, involving the sale of over 13 million shares of common stock and pre-funded warrants. Jefferies has initiated coverage on Jade Biosciences with a Buy rating, highlighting positive prospects for JADE101, the company’s treatment for IgA nephropathy. These developments reflect Jade Biosciences’ ongoing efforts to advance its therapeutic pipeline and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.